WuXi Biologics (Cayman) Inc.
Research WuXi Biologics (Cayman) Inc. (2269.HK) on Bullrun: market cap HKD 142.15B, P/E 25.8. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker2269.HK
- CountryHong Kong
- SectorHealthcare
- IndustryBiotechnology
- CurrencyHKD
- Market capHKD 142.15B
- P/E25.8
- Financial periodFY2025
- RevenueHKD 21.79B
- Revenue growth16.7%
- Net incomeHKD 4.91B
- Free cash flowHKD 2.61B
- Gross margin46.0%
Valuation Snapshot
latest market cap is HKD 142.15B; P/E is 25.8.
About WuXi Biologics (Cayman) Inc.
WuXi Biologics (Cayman) Inc., an investment holding company, provides end-to-end solutions and services for biologics discovery, development, and manufacturing for biologics industry in the People's Republic of China, North America, Europe, Singapore, Japan, South Korea, Australia, and Brazil. It operates through two segments: Biologics and XDC.
Frequently asked questions
What is WuXi Biologics (Cayman) Inc.'s market cap?
WuXi Biologics (Cayman) Inc.'s market capitalization is HKD 142.15B.
What is WuXi Biologics (Cayman) Inc.'s P/E ratio?
WuXi Biologics (Cayman) Inc.'s price-to-earnings (P/E) ratio is 25.8.
What does WuXi Biologics (Cayman) Inc. do?
WuXi Biologics (Cayman) Inc., an investment holding company, provides end-to-end solutions and services for biologics discovery, development, and manufacturing for biologics industry in the People's Republic of China, North America, Europe, Singapore, Japan, South Korea, Australia, and Brazil.